Acute alcoholic hallucinosis (AH) ranks second in incidence among alcoholic psychoses (AP), which require urgent medical attention [1]. According to the study by A.Yu. Egorov, the ratio of the incidence of alcoholic delirium to alcoholic hallucinosis is 2.27:1 for the group of patients with hereditary burden and 4.67:1 for the group without hereditary burden [2]. Usually, acute alcoholic hallucinosis develops against the background of withdrawal symptoms after prolonged binge drinking [1]. According to various authors, the incidence of acute alcoholic hallucinosis ranges from 5.6 % to 22.8 % [3, 4]. The frequency of occurrence of acute alcoholic hallucinosis variants is different. In a study performed by Nemkova T. I., it was found that the most common variant of acute alcoholic hallucinosis is abortive acute alcoholic hallucinosis — 51 %. [5]. Among other variants, the following frequencies of occurrence were noted: typical acute alcoholic hallucinosis — 31 %, with elements of Kandinsky-Clerambo syndrome — 5 %, with a predominance of visual hallucinations — 4 %, with a predominance of delusional disorders — 3 %, with a predominance of depression — 1 % [5]. Antipsychotic medicinal products such as haloperidol are considered the therapy of choice for the treatment of AP [6].

Haloperidol was synthesized in the 1950s and is used to treat schizophrenia, bipolar disorder, Tourette’s syndrome, hyperactivity, and intractable hiccups [7]. Haloperidol belongs to the first generation antipsychotics and belongs to butyrophenone derivatives, has a quick neuroleptic effect, rapidly inhibits the activity of conditioned and unconditioned reflexes [8].

Haloperidol belongs to the group of typical antipsychotic medicinal products and has a predominantly antidopaminergic effect through a pronounced effect on D2 dopamine receptors and a less pronounced effect on D1 and D4 dopamine receptors. It prevents the onset of hallucinations by blocking D2 dopamine receptors [9].